{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Neutrophil engraftment was defined as the first of 3 consecutive days with absolute neutrophil count (ANC) \\>0.5 × 10 \\^9/L. Platelet engraftment was defined as the first of 3 consecutive days of platelet count \\>20 × 10 \\^9/L without platelet transfusion in the prior 7 days. Number of participants with neutrophil and platelet engraftment failure was reported.","groups":[{"description":"Participants received single dose of tinostamustine 180 mg/m\\^2 IV injection on Day -1 followed by ASCT on Day 1.","id":"OG000","title":"Tinostamustine 180 mg/m^2"},{"description":"Participants received single dose of tinostamustine 220 mg/m\\^2 IV injection on Day -1 followed by ASCT on Day 1.","id":"OG001","title":"Tinostamustine 220 mg/m^2"}],"populationDescription":"The study was early terminated on 17 April 2019, due to safety signals during Phase 1. Hence, data for this outcome measure was not collected as planned, analyzed and reported at specific time point.","reportingStatus":"POSTED","timeFrame":"up to 6 months","title":"Phase 1 and 2: Number of Participants With Neutrophil and Platelet Engraftment Failure","type":"SECONDARY"}